Cappella, Inc., a Galway, Ireland-based medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries, has completed the second tranche of a €10.5m Series D financing.
The round includes investment from KfW and and venture loan financing from Kreos Capital Limited and Silicon Valley Bank.
Founded in 2004 by and led by CEO Dr. Art Rosenthal, Cappella has developed the Sideguard® coronary sidebranch technology that offers interventional cardiologists an easy to use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift.
The company intends to use the funds to expand sales and distribution activities of its Sideguard stent system in Europe, South America and Asia.
Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc.